Article Text

PDF

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  1. Richard Hughes
  1. Department of Neuroimmunology, Guy’s, King’s and St Thomas’ School of Medicine, Guy’s Hospital, London SE1 1UL, UK; Email: richard. a.hughes{at}kcl.ac.uk

    Abstract

    INTRODUCTION

    Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is uncommon but important. It can be disabling but is usually treatable, and probably underdiagnosed. The only population-based studies suggest a prevalence of one or two per 100 000 but these are probably underestimates because of lack of referral or recognition of cases (Lunn et al. 1999; McLeod et al. 1999). In our population-based study of 46 patients in the south-east of England, 13% required an aid to walk and 54% were receiving medical treatment on the prevalence date (Lunn et al. 1999). The natural history of untreated disease is not known but two old large series included 7–35% of patients who eventually became bedridden or died from their disease (Dyck et al. 1975; Prineas & McLeod 1976). In a more recent large series, improvement with treatment was only partial, relapses were frequent, and 60% of patients were left with disability or continued

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.